深圳市易瑞生物技术股份有限公司 独立董事关于第二届董事会第二十三次会议 相关事项的独立意见 根据《上市公司独立董事规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《上市公司独立董事履职指引》等相关规定， 作为深圳市易瑞生物技术股份有限公司（以下简称"公司"）的独立董事，基于 独立判断的立场，在仔细阅读相关材料和充分核查实际情况的基础上，现就公司 第二届董事会第二十三次会议相关审议事项发表如下独立意见： 一、关于进一步明确公司向不特定对象发行可转换公司债券方案的独立意 见 公司董事会根据股东大会授权，按照相关法律法规的要求，结合公司的实际 情况和市场状况，进一步明确了公司向不特定对象发行可转换公司债券的具体方 案。 经核查，我们认为：公司本次向不特定对象发行可转换公司债券的具体方案 符合《中华人民共和国公司法》《中华人民共和国证券法》《上市公司证券发行 注册管理办法》等法律、法规及规范性文件的规定，方案合理、切实可行，符合 公司实际情况和全体股东的利益，不存在损害中小股东利益的情形。 我们一致同意公司向不特定对象发行可转换公司债券的方案。 三、关于开设向不特定对象发行可转换公司债 ...

证券代码：300942 证券简称：易瑞生物 公告编号：2023-066 深圳市易瑞生物技术股份有限公司 第二届董事会第二十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市易瑞生物技术股份有限公司（以下简称"公司"、"发行人"或"易 瑞生物"）于2023年8月15日（星期二）在深圳市宝安区留仙一路2-1号易瑞生物 会议室以现场与通讯表决相结合的方式召开了第二届董事会第二十三次会议。本 次会议通知已于2023年8月12日以电子邮件、微信等方式送达全体董事。 本次会议由董事长朱海先生召集并主持，本次会议应出席董事9人，实际出 席董事9人（现场出席2人，通讯出席7人）；公司全体监事、高级管理人员列席 了本次会议。本次会议的召集、通知、召开和表决程序均符合《公司法》等有关 法律、行政法规、规范性文件、部门规章及《公司章程》的有关规定，会议合法、 有效。 二、董事会会议审议情况 经与会董事审议并以书面记名投票的方式对本次会议的议案进行了表决，审 议结果如下： 1、逐项审议通过《关于进一步明确公司向不特定对象发行可转换公司债券 ...

东兴证券股份有限公司 关于深圳市易瑞生物技术股份有限公司 创业板向不特定对象发行可转换公司债券 之 发行保荐书 保荐机构（主承销商） （北京市西城区金融大街5号（新盛大厦）12、15层） 二〇二三年八月 深圳市易瑞生物技术股份有限公司 向不特定对象发行可转换公司债券之发行保荐书 声明 东兴证券股份有限公司（以下简称"保荐机构"、"东兴证券"）接受深圳市 易瑞生物技术股份有限公司（以下简称"易瑞生物"、"公司"或"发行人"）的 委托，担任其向不特定对象发行可转换公司债券的保荐机构。 一、保荐机构指定相关人员基本情况 本保荐机构及保荐代表人根据《中华人民共和国公司法》（下称"《公司法》"）、 《中华人民共和国证券法》（下称"《证券法》"）、《证券发行上市保荐业务管理办 法》（下称"《保荐管理办法》"）、《上市公司证券发行注册管理办法》（以下简称 "《注册管理办法》"）、《可转换公司债券管理办法》、《深圳证券交易所创业板股 票上市规则（2023 年修订）》（下称"《上市规则》"）等有关法律、行政法规和中 国证券监督管理委员会（下称"中国证监会"）、深圳证券交易所的规定，诚实守 信，勤勉尽责，严格按照依法制订的业务规 ...

证券代码：300942 证券简称：易瑞生物 公告编号：2023-068 深圳市易瑞生物技术股份有限公司 向不特定对象发行可转换公司债券发行公告 保荐人（主承销商）：东兴证券股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示 深圳市易瑞生物技术股份有限公司（以下简称"易瑞生物"、"发行人"或"公 司"）、东兴证券股份有限公司（以下简称"保荐人（主承销商）"或"东兴证券"） 根据《中华人民共和国证券法》、《证券发行与承销管理办法》（证监会令〔第 208 号〕）、《上市公司证券发行注册管理办法》（证监会令〔第 206 号〕）（以 下简称"《注册管理办法》"）、《深圳证券交易所上市公司证券发行与承销业务 实施细则》（以下简称"《实施细则》"）（深证上〔2023〕101 号）、《深圳证 券交易所上市公司自律监管指引第 15 号——可转换公司债券》（深证上〔2022〕 731 号）、《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理 （2023 年 2 月修订）》（深证上〔2023〕135 号）等相关规定向不特定对象发行 可转换公司债券（ ...

证券代码：300942 证券简称：易瑞生物 公告编号：2023-067 深圳市易瑞生物技术股份有限公司 第二届监事会第二十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市易瑞生物技术股份有限公司（以下简称"公司"、"发行人"或"易 瑞生物"）于2023年8月15日（星期二）在深圳市宝安区留仙一路2-1号易瑞生物 会议室以现场与通讯表决相结合的方式召开了第二届监事会第二十三次会议。本 次会议通知已于2023年8月12日以电子邮件、微信等方式送达全体监事。 本次会议由监事会主席李美霞女士召集并主持，本次会议应出席监事3人， 实际出席监事3人；公司董事会秘书列席了本次会议。本次会议的召集、通知、 召开和表决程序均符合《公司法》等有关法律、行政法规、规范性文件、部门规 章及《公司章程》的有关规定，会议合法、有效。 1 本次可转换公司债券发行总额为不超过人民币 32,819.67 万元（含人民币 32,819.67 万元），发行数量为 3,281,967 张。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 1.2 ...

证券代码：300942 证券简称：易瑞生物 公告编号：2023-065 深圳市易瑞生物技术股份有限公司 关于投资者热线的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳市易瑞生物技术股份有限公司（以下简称"公司"）为了进一步加强与 投资者之间的沟通和交流，方便投资者及时了解公司情况，现设置投资者热线直 线电话，直线号码为：0755-23095742。 上述投资者热线自本公告发布之日起正式启用，原投资者热线号码0755- 27948546转889继续有效。公司联系地址、传真、投资者电子邮箱等其他联系方 式均保持不变。敬请广大投资者注意。 特此公告。 深圳市易瑞生物技术股份有限公司 董事会 2023年8月9日 1 ...

证券代码：300942 证券简称：易瑞生物 编号：2023-002 投资者关系活动记录表 特定对象调研（线下） 分析师会议 投资者关系活 媒体采访 业绩说明会 动类别 新闻发布会 路演活动 现场参观 其他 参与单位名称 及人员姓名 线上参与公司 2022 年度网上业绩说明会的投资者 时间 2023 年 5 月 17 日 15:00-17:00 地点 全景网"投资者关系互动平台"（http://ir.p5w.net） 董事兼总经理肖昭理先生 上市公司接待 独立董事何祚文先生 人员姓名 财务总监兼董事会秘书万凯先生 东兴证券保荐代表人刘鸿斌先生 公司定于 2023 年 5 月 17 日（星期三）下午 15:00-17:00 在深圳 投资者关系活 证券信息有限公司提供的网上平台（全景网）举行 2022 年度网 动主要内容介 上业绩说明会，本次年度业绩说明会将采用网络远程的方式举 绍 行 ， 投 资 者 可 登 陆 全 景 网 " 投 资 者 关 系 互 动 平 台 " （http://ir.p5w.net）参与本次年度业绩说明会。 附件清单 《2022 年度网上业绩说明会互动问答主要内容记录表》 日期 2023 年 ...

为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年5月 16日（星期二）17:00前访问http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征 集专题页面。公司将在2022年度业绩说明会上，对投资者普遍关注的问题进行回 答。欢迎广大投资者积极参与。 （问题征集专题页面二维码） 证券代码：300942 证券简称：易瑞生物 公告编号：2023-045 深圳市易瑞生物技术股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市易瑞生物技术股份有限公司（以下简称"公司"）已于2023年4月26日 在巨潮资讯网（www.cninfo.com.cn）披露了《2022年年度报告》及其摘要。 为使投资者进一步了解公司2022年度经营情况，公司将于2023年5月17日（星 期三）下午15:00-17:00在全景网举行2022年度网上业绩说明会，本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资 ...

Financial Performance - The company's revenue for Q1 2023 was ¥60,707,585.25, a decrease of 79.35% compared to ¥294,001,215.63 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥28,061,115.03, representing a decline of 124.59% from a profit of ¥114,128,972.49 in the previous year[4] - The basic earnings per share decreased to -¥0.07, down 125.00% from ¥0.28 in the same period last year[4] - The company reported a revenue of RMB 60.7076 million for Q1 2023, a decrease of 79.35% year-on-year[15] - The net profit attributable to shareholders was a loss of RMB 28.0611 million, representing a decline of 124.59% year-on-year[15] - The net profit for Q1 2023 was -28,085,394.84 CNY, compared to a net profit of 114,098,297.86 CNY in the same period last year, representing a significant decline[27] - Operating profit for Q1 2023 was -33,534,213.82 CNY, down from 139,280,317.86 CNY in Q1 2022[27] - The company reported a total comprehensive income of -28,042,280.58 CNY for Q1 2023, compared to 114,017,886.19 CNY in the same period last year[28] - Basic and diluted earnings per share for Q1 2023 were both -0.07 CNY, compared to 0.28 CNY in Q1 2022[28] Cash Flow and Assets - The company reported a net cash flow from operating activities of -¥53,990,719.10, which is a 5.50% increase in cash outflow compared to -¥51,177,229.38 in the previous year[4] - Cash and cash equivalents at the end of the first quarter were CNY 212,068,033.13, down from CNY 247,451,094.68 at the beginning of the year[21] - The total cash flow from operating activities was -53,990,719.10 CNY, compared to -51,177,229.38 CNY in the previous year, showing a slight worsening in cash flow[31] - Cash and cash equivalents at the end of Q1 2023 were 211,797,625.08 CNY, down from 303,982,289.69 CNY at the end of Q1 2022[32] - The company received 64,945,294.39 CNY in cash inflows from operating activities, a decrease from 202,641,561.46 CNY in the previous year[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,202,907,829.48, a decrease of 6.20% from ¥1,282,455,601.74 at the end of the previous year[4] - As of March 31, 2023, total assets amounted to CNY 1,202,907,829.48, a decrease from CNY 1,282,455,601.74 at the beginning of the year[23] - The total liabilities decreased to CNY 262,160,828.45 from CNY 317,754,458.88[24] - Inventory decreased to CNY 83,337,947.31 from CNY 100,608,210.17, indicating a reduction in stock levels[22] - Non-current assets increased to CNY 631,158,729.22 from CNY 608,036,291.29, reflecting ongoing investments[23] Operational Highlights - The company experienced a 52.90% decrease in contract liabilities, dropping from ¥66,613,643.52 to ¥31,374,796.78, attributed to a decline in revenue from in vitro diagnostic products[7] - The company reported a significant increase in other non-current assets, which rose by 109.44% to ¥33,572,204.71 due to increased prepayments for production and R&D equipment[7] - The company plans to focus on expanding its conventional product market and developing rapid testing for food safety and animal diagnostics[15][16] - Six new patents were granted during the reporting period, including one domestic invention patent and one design patent[16] - The subsidiary, Shenzhen Ai Doctor Biotechnology Co., is enhancing its product innovation and accelerating the acquisition of new veterinary drug certificates[17] - The company has successfully launched a series of bovine early pregnancy detection products and obtained production approval for several diagnostic kits[17] - The company aims to maintain its first-mover advantage in the animal diagnostics field through product innovation and regulatory compliance[17] - The company will adjust its business focus to ensure sustainable health development in response to global market changes[16] - Shenzhen Xiupu Biotechnology Co., Ltd. was recognized as a high-tech enterprise, with the certificate number GR202244205593, valid for three years from December 19, 2022[18] - The company registered 18 new Class II medical device products domestically, including IL-6, Myo, and SAA testing kits, enhancing its product portfolio in various medical fields[19] Investment and Expenses - The company incurred financial expenses of -671,493.01 CNY in Q1 2023, a decrease from 109,037.25 CNY in the same period last year, reflecting better financial management[27] - The company’s investment income showed a loss of ¥3,718,625.02, a decline of 447.26% compared to a profit of ¥1,070,843.57 in the previous year[8] - Research and development expenses increased to 18,391,842.45 CNY in Q1 2023, up from 15,605,979.98 CNY in Q1 2022, indicating a focus on innovation[27] - Total operating costs for the first quarter were CNY 94,325,423.68, compared to CNY 155,220,845.49 in the previous year[25] - The company reported a gross profit margin decline, with operating costs at CNY 45,522,665.69 against the revenue of CNY 60,707,585.25[25] - Investment activities generated a net cash flow of 23,962,684.77 CNY in Q1 2023, compared to 15,956,035.85 CNY in Q1 2022, indicating improved investment performance[31]

Financial Performance - The company reported a total revenue of RMB 400 million for the year 2022, representing a year-on-year increase of 15%[7]. - The company reported a gross margin of 60%, maintaining a stable profitability despite market fluctuations[7]. - The company reported a total revenue of 35,664.99 million CNY with a net profit of 5,818.68 million CNY for the period[139]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a growth of 25% year-over-year[179]. - The company reported a significant increase in revenue for 2022, with total revenue reaching CNY 1.5 billion, representing a year-on-year growth of 25%[193]. - The company achieved a remarkable 397.14% increase in international revenue, which reached approximately ¥303.46 million, compared to ¥61.04 million in the previous year[96]. - The company’s revenue from the food rapid testing business was ¥184,943,164.19, with a gross margin of 67.00%, showing a year-on-year increase of 1.32% in revenue but a decrease of 5.28% in gross margin[97]. - The in vitro diagnostic business generated approximately ¥499.44 million, which is 72.71% of total revenue, showing a significant year-on-year growth of 20.34%[95]. - The company’s total assets reached RMB 178,002,948.00 by the end of the reporting period[128]. - The total assets of the company reached 2 billion RMB, with a debt-to-equity ratio of 0.5, indicating a strong financial position[179]. Profitability and Earnings - The net profit attributable to shareholders decreased by 64.92% to ¥82,965,490.95 in 2022 from ¥236,507,393.22 in 2021[24]. - Basic earnings per share fell by 65.00% to ¥0.21 in 2022 from ¥0.60 in 2021[24]. - The net profit after deducting non-recurring gains and losses was ¥65,469,565.40, down 69.36% from ¥213,698,482.19 in the previous year[24]. - The company’s continuous operating capability is uncertain as indicated in the latest audit report[24]. - The company achieved a gross margin of 60%, reflecting improved operational efficiency and cost management[179]. - The company reported a gross margin improved to 60% in 2022, up from 55% in 2021, reflecting better cost management and pricing strategies[199]. Research and Development - Research and development expenses increased by 25% in 2022, reflecting the company's commitment to innovation[7]. - The company invested 111.42 million yuan in R&D, representing a 53.82% increase from the previous year[80]. - The company’s R&D investment amounted to ¥111,417,764.52 in 2022, representing 16.22% of its operating revenue[108]. - The number of R&D personnel increased by 16.28% from 172 in 2021 to 200 in 2022, with R&D personnel now accounting for 31.00% of the total workforce[108]. - The company has maintained a high level of R&D investment, resulting in a robust pipeline of innovative products and technologies, contributing to its competitive advantage[63]. - The company is focusing on developing high-throughput, automated, and information-based testing products to improve its product structure[142]. - The company is collaborating with research institutions to enhance R&D depth and breadth, focusing on protecting core technologies and retaining talent through effective incentive mechanisms[151]. Market Expansion and Strategy - The company aims to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[7]. - The company is actively expanding its market presence and product offerings in the animal diagnostics sector, driven by increasing demand for disease prevention in livestock and pets[60]. - The company is expanding its business into in vitro diagnostics and animal diagnostics, which requires enhanced management capabilities to mitigate risks associated with rapid growth[154]. - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and market reach[7]. - The company plans to optimize its POCT business structure and expand its market presence in the US and Latin America, particularly with toxicology products[143]. - The company is actively pursuing new technologies to enhance its product portfolio and competitive edge[176]. - The company is expanding its market presence, targeting an increase in international sales by 30% in the next fiscal year[193]. Product Development and Innovation - The company plans to invest in new product development, focusing on enhancing its immunological testing capabilities and expanding its product line[7]. - The company launched several new products, including a series of bovine early pregnancy detection products and various diagnostic kits, which have received production approval[86]. - The company has developed a comprehensive in-house production capability for antigens and antibodies, with over 120 self-produced antigens and 140 self-produced antibodies now in mass production, ensuring product quality stability[64]. - The company has successfully developed rapid testing products for food safety, with a significant increase in market demand driven by national regulatory improvements[54]. - The company is focusing on the rapid testing technology for food safety, which is expected to drive product performance growth as consumer awareness increases[57]. - The company is actively seeking strategic partnerships with suppliers to ensure a stable supply of critical raw materials and maintain price stability[153]. Risk Management and Compliance - The company identified potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[7]. - The company is actively monitoring policy changes in the food safety testing industry to mitigate risks associated with regulatory adjustments[148]. - The company has established a robust governance structure to ensure compliance with regulations and protect shareholder rights, particularly for minority shareholders[159]. - The company maintains independence from its controlling shareholders, ensuring autonomous operations across business, personnel, assets, and finances[160]. Shareholder and Management Structure - The company has established clear guidelines for the general manager's responsibilities and has not identified any violations of management protocols[163]. - The company has conducted multiple shareholder meetings with participation rates ranging from 66.08% to 74.95%[172]. - The company reported a total of 102,282,778 shares, with 12,427,502 shares being reduced from restricted stock[174]. - The company experienced a change in management, with several key personnel resigning, including the former General Manager, Lu Hehua, and the former Secretary of the Board, Zhang Yukun[175]. - The company appointed new executives, including Xiao Zhaoli as General Manager and several others as Vice General Managers on May 6, 2022[175]. - The board consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[161].